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A systematic approach for the identification
of novel, serologically reactive recombinant
Varicella-Zoster Virus (VZV) antigens
Maria G Vizoso Pinto1†, Klaus-Ingmar Pfrepper2†, Tobias Janke2, Christina Noelting2, Michaela Sander2,
Angelika Lueking3, Juergen Haas1,4, Hans Nitschko1, Gundula Jaeger1, Armin Baiker1*
Abstract
Background: Varicella-Zoster virus causes chickenpox upon primary infection and shingles after reactivation.
Currently available serological tests to detect VZV-specific antibodies are exclusively based on antigens derived
from VZV-infected cells.
Results: We present a systematic approach for the identification of novel, serologically reactive VZV antigens.
Therefore, all VZV open reading frames were cloned into a bacterial expression vector and checked for small scale
recombinant protein expression. Serum profiling experiments using purified VZV proteins and clinically defined sera
in a microarray revealed 5 putative antigens (ORFs 1, 4, 14, 49, and 68). These were rearranged in line format and
validated with pre-characterized sera.
Conclusions: The line assay confirmed the seroreactivity of the identified antigens and revealed its suitability for
VZV serodiagnostics comparable to commercially available VZV-ELISA. Recombinant ORF68 (gE) proved to be an
antigen for high-confidence determination of VZV serostatus. Furthermore, our data suggest that a serological
differentiation between chickenpox and herpes zoster may be possible by analysis of the IgM-portfolio against
individual viral antigens.
Background
The Varicella-Zoster virus (VZV) is a member of the
neurotropic alphaherpesvirus subfamily of the Herpes-
viridae. VZV causes varicella (chickenpox) during pri-
mary infection and may cause herpes zoster (shingles)
as secondary disease after reactivation from latency.
Varicella can be considered as a harmless childhood
disease. However, severe outcomes in the elderly, immu-
nocompromised or resulting from congenital infection
of the fetus or newborn are dreaded [1]. A live attenu-
ated vaccine against varicella is available since 1995 and
in Germany officially recommended since 2004 for vac-
cination of children in their second year of life. The
introduction of universal varicella vaccination has sub-
stantially reduced varicella related morbidity and mortal-
ity [2,3]. Varicella vaccine was originally administered as
a single dose, but this recommendation was modified in
favour of a two dose regimen due to the occurrence of
several breakthrough varicella infections [4-6]. Break-
through varicella may occur months to years after
immunization and is caused by wild-type VZV as a
result of vaccine failure [7]. Vaccine failure is divided
into two types. Primary vaccine failure occurs when no
measurable immune response is elicited following vacci-
nation, leaving the vaccinee susceptible to the disease.
Secondary vaccine failure occurs when the immune
response vanishes over time, leaving the vaccinee with a
degree of susceptibility to the disease [2,8]. Waning of
varicella immunity is of particular public health interest,
since it may result in an increased susceptibility later in
life, when the risk of severe complications may be
greater than during childhood. Two main reasons are
discussed for the phenomenon of waning varicella
immunity, one being the decreased immune response
and immunological memory elicited by the attenuated
varicella, the other one being the reduction in (natural)
* Correspondence: baiker@mvp.uni-muenchen.de
† Contributed equally
1Max von Pettenkofer-Institute, Virology, Munich, Germany
Vizoso Pinto et al. Virology Journal 2010, 7:165
http://www.virologyj.com/content/7/1/165
© 2010 Vizoso Pinto et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
exogenous booster exposures to VZV as a consequence
of systematic mass vaccination programmes and the
reduced circulation of this virus in the human popula-
tion [2,8].
One major goal of VZV-specific laboratory diagnosis is
the identification of immunological markers that corre-
late with protection against varicella. Such markers are
extraordinarily important, since the diagnosis of suscept-
ibility to the disease implies therapeutic consequences as
for example active or passive immunization within
certain person groups [6]. It is generally accepted that
the presence of VZV-specific antibodies within immuno-
competent persons serves as an immune correlate of
protection, indicating immunity towards varicella dis-
ease. VZV-specific antibodies are directed against a vari-
ety of different viral antigens including glycoproteins
(gps) as well as regulatory and structural proteins or
viral enzymes [9]. Antibodies of special interest are
those directed against VZV glycoprotein E (gE), since
this viral protein has been shown to be the most abun-
dant and immunogenic of all VZV gps eliciting both,
the formation of neutralizing antibodies and the media-
tion of cellular cytotoxicity [10,11]. The relative impor-
tance of the individual protein-specific antibodies in
prevention of reinfection, however, is not completely
understood.
In this work we present a systematic strategy for
screening and identification of novel, serologically reac-
tive VZV antigens based on recombinant, bacterially
expressed and purified VZV proteins (see Additional file
1). For this purpose, all 71 known VZV open reading
frames (ORFs) were recombinatorially cloned into
bacterial expression vectors. A systematic small scale
protein expression and purification study in E. coli
Rosetta (DE3) revealed, that ~35.2% of all VZV proteins
could be expressed recombinantly, and ~25.4% of all
VZV proteins could be purified in 96 well format. When
we performed serum profiling experiments with clini-
cally defined VZV patient sera in a microarray format,
~27.8% of the purified VZV proteins could be identified
as putative serological marker antigens. The respective
recombinant antigens were purified in large scale as
described by Soutscheck et al. [12], rearranged in line
assay format and validated with a number of pre-charac-
terized serum samples. These validation data confirmed
the seroreactivity of the identified marker antigens and
revealed the suitability of the recombinant line assay for
VZV serodiagnostics.
Results
Serum profiling experiments in microarray format
24 VZV proteins could be expressed in small-scale in
E. coli Rosetta (DE3) but only 18 of them (75%) could
be purified by means of Ni-NTA columns under these
conditions. Respective 18 purified VZV antigens,
namely: ORFs 1, 4, 9a, 14, 16, 18, 20, 32, 33.5, 39, 43,
49, 56, 60, 61, 62, 63 and 68 were spotted onto a micro-
array with a capacity for 34 spots (recomDot system,
Mikrogen). For control reasons we additionally spotted
a VZV lysate (Virion, Serion, Germany). All antigens
were spotted in duplicate.
For IgG monitoring, the microarrays were probed with
clinically defined sera from acute chicken pox (n = 4),
acute zoster (n = 9), and serologically defined VZV-IgG/
IgM negative control sera (n = 5). The VZV lysate was
nonreactive with all negative control sera and reactive
with 13 clinically defined sera. Three of the recombinant
antigens (ORFs 32, 33.5 and 63) reacted positive with one
negative control serum. All other antigens were negative
or inconclusive with all negative sera. ORF68 was positive
with 12 (plus 1 inconclusive) out clinically defined sera
tested. ORF1 reacted with one negative control sample.
ORF49 was negative within all negative control samples
but reacted with 6 out of 9 zoster patients. All other VZV
antigens did not show any tendency towards one of the
respective patient groups (data not shown).
When screening the same sera for IgM reactivity, the
VZV lysate was reactive with 6 clinically defined sera.
Only 4 of the recombinant VZV antigens were IgM
reactive with at least one clinically defined serum: ORF4
(n = 1), ORF9a (n = 1), ORF20 (n = 4), and ORF68 (n = 1)
and were not reactive in any negative sera tested. The
reactivities of ORF9a and ORF20 were slightly above the
cutoff level, those of ORF4 and ORF68 were significantly
higher (data not shown).
According to these results, we selected ORFs 1, 4, 14,
49 and 68 for recloning, reexpression and repurification
in large scale in order to apply these antigens onto a
line assay (recomLine VZV).
Evaluation of the identified VZV antigens by a line assay
VZV IgM and IgG reactivities in clinically defined sera
Nitrocellulose strips were coated with the selected VZV
antigens and tested with clinically characterized sera
from acute chickenpox (n = 5), acute zoster (n = 18)
and serologically defined VZV-IgG/IgM negative control
sera (n = 24) for the presence of IgG and IgM antibo-
dies (Table 1). All clinically defined sera were addition-
ally characterized by VZV IgG/IgM wcELISA (see
Additional file 2). In our recomLine VZV-IgG assay
none of the negative control sera was reactive against
recombinant ORFs 1 and 68 (Figure 1A). However,
ORFs 4, 14, and 49 were cross-reactive with IgG in
some VZV-IgG/IgM negative serum samples. No corre-
lation between cross-reactivity and HSV-IgG status
could be observed (Figure 1A, see Additional file 3).
Interestingly, ORF1 was only reactive with IgG of zoster
sera (Figure 1A), which may be a hint pointing to ORF1
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as a possible zoster marker candidate. In the recomLine
VZV-IgM assay, none of the negative control serum
samples was reactive with any recombinant antigen
(Figure 1B). Interestingly, chickenpox and herpes zoster
patients could be characterized by their IgM-portfolio
against the various recombinant proteins. Whereas sera
derived from chickenpox patients exhibited the tendency
to react with several recombinant proteins (ORFs 4, 14,
49 and 68), sera derived from herpes zoster patients
only reacted with ORF68 or showed no reactivity
towards any recombinant protein (Figure 1B, see Addi-
tional file 2). This indicates that a serological differentia-
tion between chickenpox and herpes zoster may be
possible by analysis of the IgM-portfolio against indivi-
dual viral antigens. The VZV-IgG detection limit of our
novel recomLine VZV has been determined as 250
mIU/ml by using two-fold serial dilutions of a WHO
VZV standard (50 IU/ml) reagent. The WHO VZV stan-
dard reagent exhibited only reactivity against ORF68,
but not against other antigens (data not shown).
VZV IgM and IgG reactivities in healthy donor sera
In a second series of experiments, we tested 100 samples
of healthy blood donors using the standard wcELISA
and our newly developed recomLine VZV (Table 2). We
found that the diagnostic potential of the recomLine
VZV is comparable to the Enzygnost wcELISA. When
the antigens were analyzed individually, the frequencies
of the reactivities varied from 7% (ORF1) to 97%
(ORF68) among the healthy blood donors (Figure 1C).
Due to the unweighted n for each group, we could not
determine if there is a correlation between age and the
reactivity to a certain VZV antigen. When testing IgM
antibodies, we could only find reactivities against
ORF14, ORF49 and ORF68 in five, two and three out of
100 tested samples, respectively (data not shown).
Time course of VZV seroconversion - a case report
In addition, we analyzed a time course of serocon-
version of a person with primary varicella infection.
The immunocompetent patient presented a typical
varicella skin rash and fever and seroconverted in IgG
and IgM as detected by wcELISA and the recomLine
VZV assay between days 2 and 6 after the first onset of
symptoms (Figure 2). ORF1 did not react with neither
IgG, IgA nor IgM antibodies at any time point, whereas
ORF4 reacted very weakly with IgG and IgM. ORF68
was the only antigen that reacted with the three types of
antibodies tested (IgM, IgG and IgA) and reached the
highest intensity at day 15. IgA was clearly less reactive
than IgM or IgG and the levels of anti-ORF68 declined
below the cut-off level by day 27. ORF14 and ORF4 only
reacted with IgM antibodies peaking around day 6 and
15 after the first onset of symptoms, respectively and
declining at day 27 (Figure 2).
Discussion
Virtually all currently available commercial tests for
the detection of VZV-specific antibodies, i.e. Fluores-
cent antibody to membrane antigen (FAMA), latex
agglutination (LA) and ELISA, are exclusively based on
whole antigens or antigen extracts derived from VZV-
infected cell culture and therefore lack the ability to
differentiate between antibodies directed against indivi-
dual VZV proteins. FAMA can be considered as the
gold standard test and has been shown to correlate
best with susceptibility to and protection against vari-
cella. The FAMA test principle is indirect immuno-
fluorescence microscopy using VZV-infected cells as
antigen [13]. This strategy optimally preserves the con-
formational structure of surface membrane proteins,
being responsible for the extraordinary sensitivity of
Table 1 Validation of the recomLine VZV with clinically defined sera
A
ss
a
y
R
e
su
lt
Clinically defined sera Serologically defined VZV-IgG/IgM Neg serad
Chickenpox Zoster
IgG IgM IgG IgM IgG IgM
E
L
IS
A
Pos a 5 5 18 9 0 0
Inc b 0 0 0 0 0 0
Neg c 0 0 0 9 24 24
R
e
c
o
m
L
in
e
V
Z
V
Pos 5 5 17 11 0 0
Inc 0 0 1 0 0 0
Neg 0 0 0 7 24 24
NOTE. Data are no. of serum samples.
a Pos: positive; bInc: inconclusive; cNeg: negative, d: as assayed by Siemens Enzygnost VZV IgG/IgM wcELISA.
RecomLine VZV strips were considered as positive when the intensity of the ORF68 band was higher than the cut-off band control.
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Figure 1 A) Frequency of IgG reactivity of clinically defined samples and serologically defined VZV-IgG/IgM negative samples, (*) as
assayed by Enzygnostic wcELISA, to selected recombinant VZV antigens . B) Frequency of IgM reactivity of clinically defined samples and
serologically defined VZV-IgG/IgM negative samples, (*) as assayed by Enzygnostic wcELISA, to selected recombinant VZV antigens. C) Frequency
(%) of reactive serum samples (IgG) against specific VZV antigens in a panel of 100 blood donors grouped according to age. Single VZV antigen
bands were considered as positive when their intensity was higher than the cut-off band control.
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this assay. FAMA titers of ≥ 1:4 strongly correlate with
protection from varicella after household exposure
[14]. However, the FAMA procedure is labor-intensive,
needs considerable experience in handling VZV and
cannot be automated.
LA, based on latex particles coated with extracted
VZV gps, has been reported to correlate well with
FAMA [4,8,15]. Disadvantages of LA are, that test inter-
pretation requires experience in reading agglutination, that
it cannot distinguish between various antibody subclasses
(e.g. IgG and IgM), and it is not amenable to automation.
Furthermore, false-negative results due to prozone forma-
tion, and false-positive results have been described [16,17].
ELISA based tests can be classified according to the
kind of VZV-antigens used. Whole cell ELISA (wcE-
LISA) tests, the majority of commercially available VZV-
ELISA tests, use whole lysates of VZV-infected cells as
antigen, whereas the more sensitive glycoprotein ELISA
(gpELISA) tests utilize VZV-gp extracts [15]. The origi-
nal gpELISA method has been developed by Merck for
extensive studies of children immunized with the
Varivax Oka vaccine [18,19] and is not commercially
available. However, similar gpELISA tests with high sen-
sitivity have been introduced by different companies, as
e.g. Virion/Serion and Ridascreen, recently [20,21].
For the development of novel serological tests to
detect VZV-specific antibodies it is important to keep in
mind, that assays with low sensitivity may result in
unnecessary vaccinations, which are costly to the public
health system, and assays with low specificity are prone
to produce false-positive results, mistakenly depriving
persons at risk of varicella of an indicated therapy. After
establishing of mass vaccination programmes within
many industrialized countries, primary and secondary
vaccine failures have occurred in parallel with the obser-
vation of waning immunity to VZV primary disease
after varicella vaccination. Hence, the identification of
novel varicella immune correlates of protection and the
consequently development of novel serological tests is
strongly desirable [15].
Here we present a pipeline for the screening of novel
serological markers of (in this case: VZV) infection. By
using this systematic approach we could identify five
Table 2 Comparison of the recomLine VZV prototype
with wcELISA in healthy blood donors
Result wc ELISA recomLine VZV
IgM IgG IgM IgG
Posa 1 95 1 97
Incb 4 3 0 0
Negc 95 2 99 3
Specificity
Gold standard
98.08d - 100.0e %
Sensitivity 95.15e - 97.96d %
NOTE. Data are no. of serum samples unless otherwise indicated.
a Pos: positive
b Inc: inconclusive
c Neg: negative
To calculate sensitivity and specificity, the inconclusive results were grouped
as dnegative or as epositive.
RecomLine VZV strips were considered as positive when the intensity of the
ORF68 band was higher than the cut-off band control.
Figure 2 Time course of seroconversion of an adult suffering a primary chicken-pox infection as determined by a VZV-Line assay,
wcELISA and gpELISA . Single VZV antigen bands were considered as positive when their intensity was higher than the cut-off band control.
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antigens (ORFs 1, 4, 14, 49 and 68) that were serologi-
cally reactive as recombinant, bacterially expressed pro-
teins. It is noteworthy, that all identified antigens are
components of the mature VZV virion: ORF14 and
ORF68 are both glycoproteins anchored in the viral
envelope [10]; ORF1 is a tail-anchored membrane pro-
tein facing the tegument with its N-terminus [22] and
ORF4 and ORF49 are both viral tegument proteins
[23,24]. Furthermore, ORF4 has also been identified as a
novel target protein for persistent VZV specific CD4+ T
cells, which may be involved in the control of VZV reacti-
vation [25]. ORF68 has already been described as highly
immunogenic VZV protein, eliciting both, humoral and
cellular immune responses [11,26]. Recently, recombinant
ORF68 has been utilized for the development of serologi-
cal herpesvirus microarray [27]. With our newly developed
recomLine VZV, we could further confirm the suitability
of ORF68 as a highly confident marker for VZV serostatus.
It needs to be further investigated if recombinant ORF68
alone may serve as antigen for the efficacy control for vari-
cella vaccination. In contrast, the novel identified antigens
(ORFs 1, 4, 14 and 49) showed other patterns of reactivity,
which should be further investigated in order to find pos-
sible correlations with different clinical entities of VZV
infection or VZV related immunity. According to the ana-
lysis of 23 clinically defined sera, anti-ORF1 IgG may be a
zoster marker candidate (Figure 1A). As suggested by the
analysis of these clinically defined sera (Figure 1B) and by
our time course of VZV seroconversion after primary
infection (Figure 2), the portfolio of IgM antibodies against
individual recombinant antigens may enable the serologi-
cal differentiation between chickenpox (ORFs 4, 14, 49,
and 68) and herpes zoster (only ORF68). The suitability of
in vitro transcribed and translated ORF14 using a self-
assembled protein microarray (NAPPA) for serodiagnos-
tics has also been proposed in parallel to this work by
Ceroni et al. [28]. However, the detailed significance of
detectable IgG and IgM antibodies against the various
recombinant antigens, within the status of VZV infections
needs to be further investigated.
Conclusions
We present a systematic approach for the identification
of novel, serologically reactive markers of infection (in
this case: VZV). The knowledge about the VZV serosta-
tus is extraordinarily important for immunocompromised
patients and pregnant women in order to take prophylac-
tic and/or therapeutic measurements after VZV exposure
[29]. The recomLine VZV assay based only on the
ORF68 recombinant protein is a reliable, relatively fast
(approximately 2.5 h), easy to handle and interpret test,
which can be used outside of traditional laboratory set-
tings such as clinics, community outreach centres and
physician practices to check for VZV-IgG serostatus.
Furthermore, as it is automatable it could also be used
for large screenings in e.g. epidemiological studies. The
relevance of the further identified antigens will be
further investigated with a larger number of specimens.
Methods
Recombinatorial cloning of VZV ORFs
The nucleotide sequences of all 71 VZV ORFs were
obtained from the ncbi http://www.ncbi.nlm.nih.gov/. BP
recombination reactions of VZV ORFs into pDONR207
(Invitrogen, Germany) were performed as described
earlier [30]. Briefly, all 71 VZV ORFs with attB-sites were
amplified by nested PCR, using the “first round PCR”
(VZV-ORF-specific) primer set: VZV-ORF-forward:
5’-AAAAAGCAGGCTCCGCC(18-22 ORF-sequence
specific nucleotides including start codon)-3’ and
VZV-ORF-reverse: 5’-AGAAAGCTGGGTC(18-22 ORF-
sequence specific nucleotides including stop codon)-3’
and the “second round PCR” (one-for-all) primer
set: One-for-all-forward: 5’-GGGGACAAGTTTGT-
ACAAAAAAGCAGGCT-3’ and One-for-all-reverse:
5’-GGGGACCACTTTGTACAAGAAAGCTGGGTC-3’.
PCR products containing VZV-ORFs and functional
attB-sites were gel purified using the QIAquick Gel
Extraction Kit (Qiagen, Germany) and recombinatorially
cloned into the attP-sites of pDONR207 using BP-
clonase II enzyme mix (Invitrogen, Germany) according
to the manufacturers’ instructions. BP reactions were incu-
bated at room temperature over night and subsequently
transformed into chemically competent E. coli DH5a.
Plasmid DNA of individual colonies grown on LB-plates
supplemented with 12.5 μg/ml gentamycin (Invitrogen,
Germany) was isolated using the QIAprep Spin Miniprep
Kit (Qiagen, Germany) and the integrity of the resulting
pENTR207-VZV-ORF vectors was verified by BanII (New
England Biolabs, Germany) restriction analysis and for-
ward sequencing (AGOWA, Germany).
LR recombination reactions using LR-clonase II
enzyme mix (Invitrogen, Germany) were performed
according to the manufacturers’ instructions. Briefly,
pENTR207-VZV-ORF vectors containing VZV-ORFs
flanked by attL-sites were recombinatorially cloned
into the attR-sites of the customized vector pETG-
A-His-N-[rfB]. The latter vector has been constructed
by insertion of a customized cassette consisting of
5’-NheI-HindIII-ATG-[RGS-His-tag]-EcoRV-[ccdB/
CmR(rfB)]-EcoRV-XbaI-SalI-3’ into the backbone of
the bacterial expression vector pET-22b(+) (Novagen,
Germany). LR clonase reactions were incubated at 37°C
for 2 h and subsequently transformed into chemically
competent E. coli DH5a. Plasmid DNA of individual
colonies grown on LB-plates supplemented with
100 μg/ml ampicillin (Sigma-Aldrich, Germany) was
isolated as described above and the integrity of the
Vizoso Pinto et al. Virology Journal 2010, 7:165
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resulting pETG-A-His-N-VZV-ORF vectors was verified
by HindIII/XbaI (New England Biolabs, Germany)
restriction analysis.
Small scale expression and purification of His-tagged VZV
proteins
Systematic small scale protein expression and purifica-
tion was performed as described recently [31] with
minor modifications. Briefly, all 71 constructed pETG-
A-His-N-VZV-ORF vectors were transformed individu-
ally into chemically competent E. coli Rosetta (DE3).
Transformed bacteria were selected on LB-plates supple-
mented with 100 μg/ml ampicillin (Sigma-Aldrich,
Germany). Pools of ten colonies per LB-plate were
picked and resuspended in freezing media (LB-media
supplemented with 15% glycerol). The respective 71
pools of transformed bacteria were stored in a 96-well
(round bottom) plate (Genetix, UK) at -80°C until
further analysis.
For analysis of recombinant protein expression, all
steps were performed in 96-well format using a Liquida-
tor96 manual 96-channel pipetting tool (Steinbrenner,
Germany). The 96-well glycerol culture plate was thawed
and used for inoculation of 1.5 ml LB-media supplemen-
ted with 100 μg/ml ampicillin (Sigma-Aldrich, Germany)
in a 96 (round bottom) deep well block (Qiagen,
Germany). The latter block was incubated in a bacterial
shaker at 37°C over night. For induction of recombinant
protein expression, 1.4 ml LB-media were inoculated in a
fresh 96 deep well block with 100 μl of the latter over
night culture and incubated in a bacterial shaker for 3 h
at 37°C before addition of IPTG to a final concentration
of 1 mM and an additional shaking for 6 h at 37°C. The
induced bacteria were pelleted after centrifugation of the
96 deep well block at 2.000 g, resuspended in 100 μl lysis
buffer (8 M urea, 50 mM NaH2PO4, 300 mM NaCl, 10
mM imidazole, pH 8.0), and subsequently cleared by uti-
lizing a Millipore 96-well filtration (clearing) plate (Milli-
pore, Germany) according to the manufacturers’
instructions. The cleared bacterial lysates were analyzed
by SDS/PAGE followed by Western blotting using the
monoclonal mouse anti RGS-His antibody (Qiagen,
Germany) for the presence of recombinant, His-tagged
proteins.
For fast small scale recombinant protein purification,
the bacterial pools that have been detected positive for
the presence of His-tagged VZV-proteins were induced
in individual 5 ml batch cultures for 6 h at 37°C. Protein
purification under denaturating conditions was per-
formed using Ni-NTA spin columns (Qiagen, Germany)
according to the manufacturers’ instructions. Protein
purification was verified by SDS/PAGE following
Coomassie staining. Purified His-tagged proteins were
stored at -20°C until further usage.
Serum profiling experiments in microarray format
For serum profiling experiments, the small scale purified,
His-tagged VZV proteins were spotted on microarrays.
Microarrays (recomDot, Mikrogen, Germany) were
processed according to the manufacturer’s instructions.
Briefly, purified recombinant proteins and VZV lysate
(Virion/Serion, Germany) as a control were spotted on
nitrocellulose microarrays with a capacity for 34 spots
(recomDot system, Mikrogen, Germany). All antigens
were spotted in duplicate. Arrays were incubated with
2 ml diluted serum (1:40 in recomDot buffer, Mikrogen,
Germany). For detection of specifically bound antibodies
anti-human IgG- and anti-human IgM-peroxidase conju-
gates (Seramun, Germany) were used. Visualization of
immune complexes was done with tetramethylbenzidine
(TMB) colorization substrate (see Additional file 1, I).
After scanning and digitalization, the quantification of
specific signals was done with the recomDot Scan soft-
ware (recomDot system, Mikrogen, Germany). In order
to identify putative serological VZV candidate antigens,
the microarrays were probed with different clinically and
serologically defined patient sera. Clinically defined
serum samples were derived from patients suffering from
acute varicella or zoster. Serologically defined serum
samples (e.g. VZV-IgG negative samples) were pre-
analyzed for the presence of VZV-IgG by the commer-
cially available Enzygnost wcELISA (Dade Behring,
Germany). All clinically defined serum samples were
additionally chracterized for their VZV-IgG and VZV-
IgM titers by Enzygnost wcELISA (Dade Behring,
Germany).
Cloning, recombinant expression and purification of
selected VZV proteins
Cloning and expression of the selected VZV proteins
(ORFs 1, 4, 14, 49 and 68) was performed as described
previously [32,33]. The recombinant antigens were
expressed in E. coli as full-length proteins, with excep-
tion of the glycoproteins, which were cloned without
transmembrane domains. The expressed proteins were
purified to high purity by standard chromatographic
methods as described before [12].
Generation and validation of a recomLine VZV assay
Individual dilutions of the purified recombinant antigens
were applied directly onto nitrocellulose membranes in
different lines. The appropriate line conditions for all
recombinant antigens were determined empirically with
standard serum samples. Membranes were blocked with
1% skim milk solution in phosphate-buffered saline, air
dried, and cut into individual test strips. Strips were
stored at 4°C. Processing of nitrocellulose test strips was
performed following the instruction manual for recom-
Line EBV (Mikrogen, Germany) using the reagents
Vizoso Pinto et al. Virology Journal 2010, 7:165
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supplied in the kit. Briefly, serum samples were applied at
1:100 dilutions and incubated together with the nitrocel-
lulose test strips for 1 h at room temperature. Following
three washing steps of 5 min each, a second incubation
of 45 min with peroxidase-labelled secondary antibody
(anti human IgG or IgM) was performed. Strips were
stained for about 8 min using tetramethylbenzidine after
three additional washing steps of 5 min each. Controls
were used as described previously [32,33]. The scanner
OpticPro S28 (Plustek, Korea) and recomScan software
(Mikrogen, Germany) were used according to the manu-
facture’s instructions. The test interpretation may also be
easily done manually by direct comparison with the cut-
off band provided on the strip.
Additional material
Additional file 1: Systematic pipeline for the identification of novel
serological markers of VZV infection. A) Nested PCR for the
amplification of VZV ORFs with attB sites, B) BP reaction into pDONR207,
C) Characterization of resulting pENTR207 vectors by BanII restriction
analysis and sequencing, D) LR reaction to insert the customized
bacterial expression vector pETG-A-His-N- [rfB], E) Characterization of
resulting pETG-A-His-N-VZV-ORF vectors by HindIII and XbaI restriction
analysis and sequencing, F) Transfection of expression vectors into E. coli
Rosetta (DE3) and induction of protein expression with IPTG, G) Analysis
of protein expression by Western blotting using an anti-RGS-His
antibody, H) Analysis of purified proteins by SDS-PAGE and Coomassie
staining, I) Screening for serologically reactive antigens in microarray
format, J) Rearrangement of screened marker antigens in Line format.
Additional file 2: Validation of the VZV RecomLine with clinically
defined serum samples. This table depicts all serological parameters of
the clinically defined patient sera.VZV-IgG and IgM ELISA titres were
assayed by wcELISA (Dade Behring, Enzygnost, Germany). Qualitative
RecomLine VZV IgG and IgM reactivities towards individual antigens are
depicted as “1” (reactive) and “0” (non reactive).
Additional file 3: Analysis of possible crossreactivities of the
RecomLine VZV recombinant antigens with serum samples of
defined antibody status to HSV. This table depicts the cross-reactivity
of all serologically defined VZV-IgG negative patient samples according
to their HSV (IgG) status. No cross-reactivity in the in the RecomLine VZV
IgM assay can be observed. The recomLine VZV IgG assay exhibits some
reactivities against ORFs 4, 14, 49 but not against ORF68. No correlation
of cross-reactivities and HSV-1 status can be observed.
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